Comparative Pharmacology
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus SSD AF.
ELASE-CHLOROMYCETIN vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
Topical application: Apply thin layer to affected area 2-3 times daily.
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic and Debriding Agent
Topical Antibiotic